Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hong Gao

Gastroenterology Tallahassee, FL Medical Doctor

NPI 1376502740 CMS profile 16339

2400 Miccosukee Rd, Tallahassee, FL 32308

Open in the dashboard

General payments

$9,081

482 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hong Gao of Tallahassee, FL is reported in the CMS Open Payments database as having received $9,081 across 482 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,492 78
2024 General $1,130 68
2023 General $1,628 80
2022 General $1,791 95
2021 General $1,800 82
2020 General $370 25
2019 General $868 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hong Gao
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Hong Gao were reported at $1,492. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Hong Gao Gastroenterology median Middle half National median
2019 $868 $417 $126–$1,100 $163
2020 $370 $224 $74–$624 $114
2021 $1,800 $352 $106–$1,054 $132
2022 $1,791 $448 $129–$1,270 $149
2023 $1,628 $533 $150–$1,390 $160
2024 $1,130 $605 $160–$1,606 $164
2025 $1,492 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,465 196 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $847 45 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $620 37 payments
  4. Pfizer Inc. $592 25 payments
  5. Celgene Corporation $541 31 payments
  6. Medtronic, Inc. $371 4 payments
  7. Janssen Biotech, Inc. $308 15 payments
  8. Nestle HealthCare Nutrition Inc. $292 15 payments
  9. Ardelyx, Inc. $258 14 payments
  10. Phathom Pharmaceuticals, Inc. $240 18 payments
  11. Other $1,547 82 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,361 478 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $608 2 payments
  3. Education $112 2 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,294 49 payments
  2. HUMIRA $865 55 payments
  3. LINZESS $801 49 payments
  4. CREON $743 45 payments
  5. SKYRIZI $647 47 payments
  6. XIFAXAN $593 35 payments
  7. ZEPOSIA $488 28 payments
  8. XELJANZ $423 21 payments
  9. ENTYVIO $393 22 payments
  10. ZENPEP $354 19 payments
  11. Other $4,067 206 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,090

Median for Gastroenterology: 569

Drug cost

$272,555

Median for Gastroenterology: $104,976

Branded share of claims

31.3%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira(Cf) Pen Adalimumab Brand 13 $82,614
Xifaxan Rifaximin Brand 24 $72,788
Creon Lipase/Protease/Amylase Brand 21 $55,993
Linzess Linaclotide Brand 21 $21,090
Colestipol Hcl Generic 103 $8,151
Mesalamine Er Mesalamine Brand 23 $7,049
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 77 $4,583
Omeprazole Generic 245 $3,851
Ursodiol Generic 21 $3,750
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 117 $2,834

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$127,952

Of which drugs: $32,846

Medicare patients

367

Average age 72

Services billed

2,599

239 women, 128 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 47%
Ischemic heart disease 29%
Diabetes 28%
Depression 23%
Chronic kidney disease 22%
Cancer 19%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $192
$192 — —
RINVOQ
  • AbbVie, Inc. $157
$157 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $156
$156 — —
IBSRELA
  • Ardelyx, Inc. $118
$118 — —
IQIRVO
  • Ipsen Biopharmaceuticals, Inc $74
$74 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

482 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record